|
1
|
van der Zwan JM, Mallone S, van Dijk B,
Bielska-Lasota M, Otter R, Foschi R, Baudin E and Links TP:
RARECARE WG: Carcinoma of endocrine organs: Results of the RARECARE
project. Eur J Cancer. 48:1923–1931. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu TR, Su X, Qiu WS, Chen WC, Men QQ, Zou
L, Li ZQ, Fu XY and Yang AK: Thyroid-stimulating hormone receptor
affects metastasis and prognosis in papillary thyroid carcinoma.
Eur Rev Med Pharmacol Sci. 20:3582–3591. 2016.PubMed/NCBI
|
|
3
|
Ibitoye R and Wilkins A: Thyroid papillary
carcinoma after alemtuzumab therapy for MS. J Neurol.
261:1828–1829. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Min XS, Huang P, Liu X, Dong C, Jiang XL,
Yuan ZT, Mao LF and Chang S: Bioinformatics analyses of significant
prognostic risk markers for thyroid papillary carcinoma. Tumour
Biol. 36:7457–7463. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ceresini G, Corcione L, Michiara M, Sgargi
P, Teresi G, Gilli A, Usberti E, Silini E and Ceda GP: Thyroid
cancer incidence by histological type and related variants in a
mildly iodine-deficient area of Northern Italy, 1998 to 2009.
Cancer. 118:5473–5480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Z, Xu Z, Li Z, An C, Liu J, Zhu Y,
Ni S, Tang P, Sayan A and Ilankovan V: Minimally-invasive
endoscopically-assisted neck dissection for lateral cervical
metastases of thyroid papillary carcinoma. Br J Oral Maxillofac
Surg. 52:793–797. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee T, Cha YJ, Ahn S, Han J and Shim YM: A
rare case of tumor-to-tumor metastasis of thyroid papillary
carcinoma within a pulmonary adenocarcinoma. J Pathol Transl Med.
49:78–80. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mazzaferri EL and Jhiang SM: Long-term
impact of initial surgical and medical therapy on papillary and
follicular thyroid cancer. Am J Med. 97:418–428. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haymart MR, Repplinger DJ, Leverson GE,
Elson DF, Sippel RS, Jaume JC and Chen H: Higher serum thyroid
stimulating hormone level in thyroid nodule patients is associated
with greater risks of differentiated thyroid cancer and advanced
tumor stage. J Clin Endocrinol Metab. 93:809–814. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fiore E, Rago T, Provenzale MA, Scutari M,
Ugolini C, Basolo F, Di Coscio G, Berti P, Grasso L, Elisei R, et
al: Lower levels of TSH are associated with a lower risk of
papillary thyroid cancer in patients with thyroid nodular disease:
Thyroid autonomy may play a protective role. Endocr Relat Cancer.
16:1251–1260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Medenica S, Nedeljkovic O, Radojevic N,
Stojkovic M, Trbojevic B and Pajovic B: Thyroid dysfunction and
thyroid autoimmunity in euthyroid women in achieving fertility. Eur
Rev Med Pharmacol Sci. 19:977–987. 2015.PubMed/NCBI
|
|
12
|
McNabb FM: Thyroid hormones, their
activation, degradation and effects on metabolism. J Nutr. 125
Suppl:S1773–S1776. 1995.
|
|
13
|
Glinoer D: The regulation of thyroid
function in pregnancy: Pathways of endocrine adaptation from
physiology to pathology. Endocr Rev. 18:404–433. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tomer Y, Barbesino G, Keddache M,
Greenberg DA and Davies TF: Mapping of a major susceptibility locus
for Graves' disease (GD-1) to chromosome 14q31. J Clin Endocrinol
Metab. 82:1645–1648. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gerschpacher M, Göbl C, Anderwald C, Gessl
A and Krebs M: Thyrotropin serum concentrations in patients with
papillary thyroid microcancers. Thyroid. 20:389–392. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pacini F, Schlumberger M, Dralle H, Elisei
R, Smit JW and Wiersinga W: European Thyroid Cancer Taskforce:
European consensus for the management of patients with
differentiated thyroid carcinoma of the follicular epithelium. Eur
J Endocrinol. 154:787–803. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pelizzo MR, Boschin Merante I, Toniato A,
Pagetta C, Casal Ide E, Mian C and Rubello D: Diagnosis, treatment,
prognostic factors and long-term outcome in papillary thyroid
carcinoma. Minerva Endocrinol. 33:359–379. 2008.PubMed/NCBI
|
|
18
|
Uruno T, Miyauchi A, Shimizu K, Tomoda C,
Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, Amino N, et
al: Favorable surgical results in 433 elderly patients with
papillary thyroid cancer. World J Surg. 29:1497–1503. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brabant G: Thyrotropin suppressive therapy
in thyroid carcinoma: What are the targets? J Clin Endocrinol
Metab. 93:1167–1169. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sfakianakis GN, Skillman TG and George JM:
Thyroxine withdrawal in thyroid cancer. Ohio State Med J. 71:79–82.
1975.PubMed/NCBI
|
|
21
|
Kim SS, Lee BJ, Lee JC, Song SH, Kim BH,
Son SM, Kim IJ, Kim YK and Kang YH: Preoperative serum thyroid
stimulating hormone levels in well-differentiated thyroid carcinoma
is a predictive factor for lateral lymph node metastasis as well as
extrathyroidal extension in Korean patients: A single-center
experience. Endocrine. 39:259–265. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roy PG, Pratt N, Purdie CA, Baker L,
Ashfield A, Quinlan P and Thompson AM: High CCND1 amplification
identifies a group of poor prognosis women with estrogen receptor
positive breast cancer. Int J Cancer. 127:355–360. 2010.PubMed/NCBI
|
|
23
|
Nakashima M, Meirmanov S, Naruke Y, Kondo
H, Saenko V, Rogounovitch T, Shimizu-Yoshida Y, Takamura N, Namba
H, Ito M, et al: Cyclin D1 overexpression in thyroid tumours from a
radio-contaminated area and its correlation with Pin1 and aberrant
β-catenin expression. J Pathol. 202:446–455. 2004. View Article : Google Scholar : PubMed/NCBI
|
